Tesla Motors Inc (TSLA) has Executed Like No Company has Ever Done: Drew Cupps

In less than two weeks that  Tesla Motors Inc (NASDAQ:TSLA) announced its better than expected second quarter results, a review from Consumer Reports which highlighted small issues with long term usage of Model S has given minor jitters to some Tesla Motors Inc (NASDAQ:TSLA)’s investors. The investor expectations from Tesla Motors Inc (NASDAQ:TSLA) is huge and even a small news can have a wide impact where Tesla Motors Inc (NASDAQ:TSLA) is concerned. But, not all investors have worries regarding Tesla Motors Inc (NASDAQ:TSLA)’s prospects, especially not, Drew Cupps. The Chief Investment Officer of Cupps Capital Management bought stake in Tesla Motors Inc (NASDAQ:TSLA) during its IPO, raised it over the years, and continues to sit tight on them.

He discussed the latest review from Consumer Reports and how Tesla Motors Inc (NASDAQ:TSLA) should respond to it on CNBC.

Tesla Motors Inc (NASDAQ:TSLA)

“[…] It probably comes down to the terms that we use to define unreliable car. I don’t think that’s what we heard here today, I think that people that buy a Mercedes S-class also have problems, a little this, a little that. I think the responsiveness with which Tesla Motors Inc (NASDAQ:TSLA) corrected the problems, the scope of the problems, not too bad. Remember this is the first car they have ever produced […],”  Cupps said.

Cupps feels that execution, like always, is the key and Tesla Motors Inc (NASDAQ:TSLA) should focus on that. He believes that Tesla Motors Inc (NASDAQ:TSLA)  should respond aggressively, but not specifically to the review by Consumer Reports. According to him, Tesla Motors Inc (NASDAQ:TSLA) should continue to focus on customer satisfaction and customer responsiveness.

“[…] They are reducing costs, they are increasing functionality, they are really taking the industry beyond where it has ever been and that is all what is supporting the valuation and the trajectory of the valuation,” Cupps added.

Disclosure: None

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!